bioAffinity Technologies, Inc. (BIAF)vsWaters Corporation (WAT)
BIAF
bioAffinity Technologies, Inc.
$1.73
-7.98%
HEALTHCARE · Cap: $7.66M
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 66514% more annual revenue ($3.77B vs $5.66M). WAT leads profitability with a 11.9% profit margin vs -280.6%. WAT earns a higher WallStSmart Score of 50/100 (C-).
BIAF
Avoid23
out of 100
Grade: F
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIAF.
Margin of Safety
-84.6%
Fair Value
$178.29
Current Price
$365.36
$187.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -433.7% — below average capital efficiency
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : BIAF
The strongest argument for BIAF centers on Price/Book.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : BIAF
The primary concerns for BIAF are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
BIAF profiles as a turnaround stock while WAT is a growth play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
BIAF generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 23/100) and 91.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
bioAffinity Technologies, Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?